A Big Hit But A Small Miss? Lipitor Generic Launched But Ranbaxy’s Caduet Prospects In Doubt As Mylan Storms The Market
This article was originally published in PharmAsia News
Executive Summary
A rollercoaster of a week for India’s Ranbaxy ends with yet another mystery – what is the status of its first-to-file applications for Pfizer’s Caduet?